#373 – Thyroid function and hypothyroidism: why current diagnosis and treatment fall short for many, and how new approaches are transforming care | Antonio Bianco, M.D., Ph.D.

What It Covers

Dr. Antonio Bianco explains why current hypothyroidism diagnosis relies too heavily on TSH alone, how tissue-level thyroid hormone conversion through deiodinase enzymes determines actual function, and why combination T4/T3 therapy reduces mortality by thirty percent compared to standard levothyroxine monotherapy.

Key Questions Answered

• •Deiodinase enzyme function: Type 2 deiodinase (D2) produces eighty percent of active T3 outside the thyroid with 1,000-fold greater affinity than D1, while D3 inactivates thyroid hormone. Local tissue T3 levels can increase tenfold in hours without blood level changes, making peripheral measurements inadequate for assessing tissue-specific thyroid status.
• •TSH limitations in diagnosis: TSH between 0.5-4.0 with normal free T4 indicates adequate thyroid function, but free T3 plays no role in hypothyroidism diagnosis because the body defends T3 levels until severe disease develops. Secondary hypothyroidism requires low free T4 with inappropriately normal TSH, occurring in less than one percent of cases.
• •Mortality data reveals treatment gaps: Hypothyroid patients on levothyroxine monotherapy show 2.5-fold increased mortality versus healthy controls, primarily from cardiometabolic disease. Combination T4/T3 therapy reduces mortality by thirty percent compared to T4 alone, suggesting incomplete restoration of tissue thyroid status with standard treatment despite normalized TSH levels.
• •Liver metabolism remains impaired: Patients treated with levothyroxine to normal TSH ranges still require statins as the number one co-medication because liver LDL receptor function remains compromised. Animal studies confirm liver tissue stays hypothyroid despite normal circulating TSH and T4, explaining persistent elevated cholesterol requiring additional pharmaceutical intervention.
• •T3 measurement accuracy problems: Standard immunoassays for free T3 and reverse T3 lack reliability, especially at low levels where clinical decisions matter most. Mass spectrometry provides accurate T3 measurement but remains unavailable through major commercial labs. Free T4 immunoassays perform adequately, making T4 the most reliable biochemical marker for thyroid function assessment.